Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Search Search Blog Front Page CategoriesCategories Select Category ALL (1) Conferences and Papers (1) COVID-19 (26) Data Exclusivities (5) Deceptive Claims (1) Exhaustion (2) Experimental Use (1) IPAB (1) Patent Pools (2) Patents (18) Right to Health (5) TAMU (1) Trade Policy (6) TRIPS (24) TRIPS Flexibilities (6) Vaccines (6) Voluntary Licenses (1) Archives Archives Select Month July 2022 June 2022 March 2022 December 2021 November 2021 October 2021 September 2021 August 2021 July 2021 May 2021 February 2021 January 2021 December 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 Regular Contributors Doris Estelle Long (13) Srividhya Ragavan (12) Shirin Syed (4) Michael Palmedo (3) Jonathan Kimball (1) Sonal Singh (1) All Authors RECENT POSTS Call For Papers: The Eighth Annual IP Mosaic Conference Working with the Ministerial Decision on TRIPS Ministerial Decision: “TRIPped” the Waiver? Intellectual Property Law and Access to Medicines Named One of the Best New Intellectual Property Books by BookAuthority Omicron: Requires TRIPS Waiver Vaccine
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
